Mutation News and Research

RSS

Potential new biomarkers may aid early detection of glaucoma

Researchers at Ruhr-Universität Bochum have identified new potential biomarkers that may facilitate early detection of glaucoma in patients. Moreover, they ascertained that the mutation of a certain gene in mice causes intraocular pressure elevation.

25 Oct 2018

Influenza virus can evolve resistance to experimental antiviral drug

The influenza virus can evolve resistance to an anti-flu drug currently in development for use in pandemics but only if there are multiple genetic mutations, a study has found.

25 Oct 2018

Battling against resistant and sensitive types of influenza A

Another flu season is here, which means another chance for viruses to mutate. Already, most influenza A viruses contain a mutation that confers resistance against one class of antiviral medications, and the bugs are steadily gaining resistance against another class.

25 Oct 2018

Scientists engineer antiviral peptide that exploits Achilles' heel of Zika virus

Scientists at Nanyang Technological University, Singapore have engineered an antiviral peptide that exploits the Zika virus at its Achilles' heel - the viral membrane - hence stopping the virus from causing severe infections.

24 Oct 2018

How a single mutation can devastate cellular function

A scientist has shown how a single mutation in a protein found in astrocytes reproduces fibrous globs that devastate cellular function.

23 Oct 2018

Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy

Treatment with the cyclin dependent kinase 4/6 inhibitor palbociclib achieves a clinically meaningful improvement in overall survival in patients with hormone receptor positive human epidermal growth factor receptor-2 negative advanced breast cancer that has relapsed or progressed on hormonal therapy, according to the final analysis of overall survival results from the PALOMA-3 study reported at ESMO 2018.

23 Oct 2018

Drugs approved for breast cancer treatment are effective and well tolerated in men

There is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the largest real-life study yet to investigate treatment and outcomes in men with breast cancer and two further studies to be reported at ESMO 2018.

23 Oct 2018

Cancer treatment may undergo a paradigm shift to immunotherapy soon

Immunotherapy when used for cancer treatment could extend life longer finds studies. Experts have explained that until now immunotherapy was reserved as a last resort for most patients and treatment usually comprised of chemotherapy and radiation therapy failing which these were tried. In a pair of clinical trials, researchers have found that using immunotherapy as first line treatment can extend lives of these cancer patients.

23 Oct 2018

Study: Targeting specific genomic mutation in breast cancer improves survival

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.

22 Oct 2018

Epigenetic modifications may contribute to Alzheimer's Disease

Scientists report epigenetic modifications in the brains of patients with Alzheimer's, after observing differences in histone acetylation across the genome.

22 Oct 2018

Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers

Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

Two-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or 2 mutation, results from the phase 3 SOLO-1 trial show.

22 Oct 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer(NSCLC), shows a randomized study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich.

22 Oct 2018

Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for KALYDECO (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

22 Oct 2018

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the presentation today of updated preliminary results from its ongoing Phase 1 clinical study of DCC-2618, the company's broad-spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors as a proffered paper presentation at the European Society of Medical Oncology 2018 Congress in Munich, Germany.

22 Oct 2018

Researchers investigate why some cancers affect only young women

Among several forms of pancreatic cancer, one of them affects specifically women, often young. How is this possible, even though the pancreas is an organ with little exposure to sex hormones? This pancreatic cancer, known as "mucinous cyst", has strange similarities with another mucinous cancer, affecting the ovaries.

19 Oct 2018

New approach to understanding cancers will accelerate development of better treatments

A new innovation in cancer research will enable scientists to understand the complex causes of the disease with unprecedented speed and sophistication. This will accelerate the development of new and better treatments, and it will help researchers find ways around roadblocks that now stand in their path.

19 Oct 2018

Genetically modifying zebrafish provides numerous, highly accurate disease models

Research published today describes how zebrafish can be genetically engineered to produce more accurate models of human disease.

18 Oct 2018

Mutation News and Research

Potential new biomarkers may aid early detection of glaucoma

Influenza virus can evolve resistance to experimental antiviral drug

Battling against resistant and sensitive types of influenza A

Scientists engineer antiviral peptide that exploits Achilles' heel of Zika virus

How a single mutation can devastate cellular function

Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy

Drugs approved for breast cancer treatment are effective and well tolerated in men

Cancer treatment may undergo a paradigm shift to immunotherapy soon

Study: Targeting specific genomic mutation in breast cancer improves survival

Epigenetic modifications may contribute to Alzheimer's Disease

Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

Researchers investigate why some cancers affect only young women

New approach to understanding cancers will accelerate development of better treatments

Genetically modifying zebrafish provides numerous, highly accurate disease models

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News